The global antiviral drugs market size is expected to reach USD 50.02 Billion in 2030 and register a revenue CAGR of 3.4% during the forecast period, according to latest report by Reports and Data.
The global antiviral drugs market size is expected to reach USD 50.02 Billion in 2030 and register a revenue CAGR of 3.4% during the forecast period, according to latest report by Reports and Data. Increasing number of patients infected by influenza and other viral respiratory infections, especially during the COVID-19 pandemic, is driving market revenue growth. Many factors are contributing to this rapid spread of viral infectious diseases, including increasing human mobility, rise in trade and tourism, and shifting geographic distribution of disease vectors.
Access Free sample PDF Copy of the Report @ https://www.reportsanddata.com/sample-enquiry-form/1734
Human travel and migration, in particular, is a major driving force behind the global spread of viral infections. Changing environmental conditions, due to abrupt climate change, is also contributing to widespread viral infections, and this is resulting in development of novel antiviral medications, which is supporting market revenue growth. However, high costs of Research & Development (R&D) in the area of drug development is limiting market revenue growth. Furthermore, rising healthcare costs and preventive measures against viral infections are also expected to hinder revenue growth of the market during the forecast period.
Competitive Landscape:
The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as R&D investments, license agreements, partnerships, merger and acquisitions, collaborations, and joint ventures to gain robust footing in the market.
Top Companies Profiled in the Report:
GlaxoSmithKline plc., Gilead Sciences, Inc., Merck & Co., Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer Inc., and Dr. Reddy’s Laboratories Ltd.
To know more about the report, visit @ https://www.reportsanddata.com/report-detail/antiviral-drugs-market
Some Key Highlights in the Report
- On 14th March 2022, Open Philanthropy, Bill and Melinda Gates Foundation, and Novo Nordisk announced a USD 90 million initial investment in the Pandemic Antiviral Discovery (PAD) project, which will expedite antiviral drug discovery and development of medications for prevention of future potential pandemics. These core partners are engaged in making PAD-supported product innovations and discoveries available to people in developing countries. Many collaborations and partnerships between governments and private firms are taking place, which is increasing pioneering research on high-tech technologies that can drive revenue growth of this industry.
- Generic drugs segment revenue is expected to register a steady growth rate during the forecast period. Generic drugs are less expensive, as their manufacturing costs do not include marketing costs, unlike their brand-name equivalents. They are safe and effective, providing the same quality and functionality as branded drugs, and they are also easily accessible and more affordable to a wider range of people. These factors are contributing to revenue growth of this segment.
- Online pharmacy services segment revenue is expected to register a fast growth rate during the forecast period, as people, constrained by lockdowns, are more interested in home-delivery and cost-effective options with greater ease and availability of medicines. These online services also have a better range of options, which is driving revenue growth of this segment.
- Human Coronaviruses (HCoV) segment accounted for a significantly large revenue share in 2021, due to rising cases of viral infections across the globe. According to the World Health Organization (WHO) report published on September 1st, 2021, there had been 217.56 million confirmed cases of COVID-19, with 4.52 million deaths reported. This viral disease possesses a greater risk of causing future pandemics, due to its high infectivity and transmission rates, and higher viral load. This is increasing demand for antiviral drugs for treatment of such diseases.
- Antiviral drugs market in Asia-Pacific accounted for a significantly large revenue share in 2021, due to increasing public awareness about antiviral medications through healthcare programs and government policies, which is helping in improving the healthcare sector in the region. Presence of several major pharmaceutical companies in growing economies, such as India and China, is also supporting market revenue growth in the region.
Download Summary @ https://www.reportsanddata.com/download-summary-form/1734
Antiviral Drugs Market Segmentation:
Drug Type Outlook (Revenue, USD Billion; 2019-2030)
- Generic Drugs
- Branded Drugs
Application Outlook (Revenue, USD Billion; 2019-2030)
- Influenza
- Hepatitis A, B & C
- Human Immunodeficiency Virus (HIV)
- Herpes
- Respiratory Syncytial Virus (RSV)
- Human Coronaviruses (HCoV)
- Others
Regional Outlook:
- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
- Latin America (Brazil, Rest of LATAM)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Ask for Customize Research Report @ https://www.reportsanddata.com/request-customization-form/1734
This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the market’s future growth.
Explore Latest Trending Research Reports By Reports and Data’s:
Foot and Mouth Disease (FMD) Vaccine Market Share & Trends Analysis Report By Type (Conventional Vaccines, Emergency Vaccines), By Application, By Region, Competitive Strategies and Segment Forecasts to 2016-2026
Etanercept Market Size by Product (Enbrel, Benepali), by Application (Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Juvenile idiopathic arthritis (JIA) and Others), Share & Trends Analysis Report By Region, Competitive Strategies and Segment Forecasts to 2016-2026
Fluoxetine Market Size by Type (Tablets, Capsules, Oral Solutions), by Application (Depression, Obsessive-Compulsive Disorder, Panic disorder, Bulimia Nervosa and Others), Share & Trends Analysis Report By Region, Competitive Strategies and Segment Forecasts to 2016-2026
Palbociclib Market Size by Product (75mg Tablets, 100mg Tablets, 125mg Tablets), by Application (Estrogen Receptor Positive (ER+) Breast Bancer, HER2 Negative (HER2-) Advanced Breast Cancer, Metastatic Breast Cancer), By Region, Competitive Strategies and Segment Forecasts to 2016-2026
Dental Implants Market , By Type (Endosteal Implants, Subperiosteal Implants, Transosteal Implants, Intramucosal Implants), By Material (Titanium, Zirconium, Others), By Design (Tapered Implants, Parallel-Walled Implants), By Procedure Type (Root-Form, Plate-Form), By End Use (Hospitals, Dental Clinics, Others), And By Region Forecast To 2028
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs